Abstract
Factor VIII, the plasma protein deficient or defective in individuals with hemophilia A, is a critical member of the blood coagulation cascade. Recent studies have identified the FVIII light chain region Glu1811-Lys1818 as being involved in FIXa binding and in the assembly of the FX-activating FIXaz–FVIIIa complex. Based on this, a series of 12 peptides, analogues of the 1811–1818 loop of the A3 subunit of the light chain A3-C1–C2 of FVIIIa, were synthesized and evaluated for their anticoagulant activity. Only peptide Ac-ETKTYFWK-NH2 showed significant anticoagulant activity by inhibiting about 40% factor VIII at a concentration of 0.43 mM. It also showed a prolongation of activated partial thromboplastin time of 6.1 s, whereas its effect on prothrombin time measurements was meaningless. All the other peptides did not show any measurable effect at the concentration of 0.43 mM. These findings are encouraging though further investigation of the effect of this active peptide in different biological settings is needed in order to evaluate its possible clinical applications.
Similar content being viewed by others
References
Achyuthan KE, Slaughter TF, Santiago MA, Enghild JJ, Geenberg CS (1993) Factor XIIIa-derived peptides inhibit transglutaminase activity. Localization of substrate recognition sites. J Biol Chem 268:21284–21292
Barlos K, Chatzi O, Gatos D, Stavropoulos G (1991) 2-Chlorotrityl chloride resin. Studies on anchoring of Fmoc-amino acids and peptide cleavage. Int J Peptide Protein Res 37:513–520
Barrowcliffe WT, Raut S, Sands D, Hubbard RA (2002) Coagulation and chromogenic assays of Factor VIII activity: general aspects, standardization and recommendations. Semin Thromb Hemost 28:247–255
Cinotti S, Longo G, Messori A, Morfini M, Blomback M, Schimpf K (1991) Reproducibility of one-stage, two-stage and chromogenic assays of factor VIII activity: a multi-center study. Thromb Res 61:385–393
Finney S, Seale L, Sawyer RT, Wallis RB (1997) Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii. Biochem J 324:797–805
Hee-Yeon J, Won-Kyo J, Se-Kwon K (2008) Purification and characterization of a novel anticoagulant peptide from marine echiuroid worm, Urechis unicinctus. Process Biochem 43:179–184
Hirsh J (2003) Current anticoagulant therapy—unmet clinical needs. Thromb Res 109:S1–S8
Howard EL, Becker KCD, Rusconi CP, Becker RC (2007) Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol 27:722–727
Kaiser E, Colescott R, Bossinger CD, Cook PI (1970) Color test for detection of free terminal amino groups in the solid phase synthesis of peptides. Anal Biochem 34:595–598
Koutsas C, Sarigiannis Y, Stavropoulos G, Liakopoulou-Kyriakides M (2007) Conjugation of resveratrol with RGD and KGD derivatives. Protein Peptide Lett 14:1014–1020
Lenting PJ, van de Loo J-WHP, Donath M-JSH, van Mourik JA, Mertens K (1996) The sequence Glu1811–Lys1818 of human blood coagulation Factor VIII comprises a binding site for activated Factor IX*. J Biol Chem 271:1935–1940
Mertens K, Bertina RM (1985) The role of factor VIII in the activation of blood coagulation factor X by activated factor IX. Thromb Haemost 54:654–660
Ray MJ, Hawson GAT (1989) A comparison of two APTT reagents which use silica activators. Clin Lab Haematol 11:221–232
Rodgers SE, Duncan EM, Barbulescu DM, Quinn DM, Lloyd JV (2006) In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two stage-factor VIII assay results. Br J Haematol 136:138–145
Spiegel PC, Kaiser MS, Simon AS, Stoddard LB (2004) Disruption of protein-membrane binding and identification of small-molecule inhibitors of coagulation factor VIII. Chem Biol 11:1413–1422
Tae-Kyung L, Jeong-Hyun C, Jang-Woong B, Yoon-Sik L (2008) Preparation of MBHA resin by benzotriazole-mediated amidoalkylation. Tetrahedron Lett 49:5380–5382
ten Boekel E, Böck M, Vrielink GJ, Liem R, Hemdriks H, de Kieviet W (2007) Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents. Thromb Res 121:361–367
Van den Besselaar AMHP, Neuteboom J, Bertina RM (1993) Effect of synthetic phospholipids on the response of the activated partial thromboplastin time to heparin. Blood Coagul Fibrinolysis 4:895–903
Van der Velde EA, Poller L (1995) The APTT monitoring of heparin—the ISTH/ICSH collaborative study. Thromb Haemost 73:73–81
Acknowledgments
This Research Project is co-financed: 80% by European Union-European Social Fund and 20% by General Secretary Research & Technology (PENED 03ED569).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Patsialas, K., Koutsas, C., Makris, P. et al. Peptide analogues of 1811–1818 loop of the A3 subunit of the light chain A3-C1–C2 of FVIII of blood coagulation: biological evaluation. Amino Acids 39, 481–488 (2010). https://doi.org/10.1007/s00726-009-0464-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-009-0464-z